In short
Clinical trials are investigating Sisunatovir in people with respiratory syncytial virus (RSV) infection. The studies are looking at safety, tolerability, blood levels, and how different forms taste, with target groups including infants, children, and healthy adults.
Key points
- Clinical trials of Sisunatovir are early Phase 1 studies focused on RSV, including RSV lower respiratory tract infection. One study was planned for infants and children and looked at safety, tolerability, blood levels, and safety-related measures such as lab tests, ECGs, and vital signs. Another study in healthy adults looked at taste and mouth-feel ratings for different formulations. The trial data show one withdrawn study and one completed study. Overall, the research is aimed at understanding how Sisunatovir performs in different groups before larger studies.
Clinical trials overview
The available trial data show two early Phase 1 studies of Sisunatovir. One study was designed to learn about safety, tolerability, and blood levels in infants and children with RSV lower respiratory tract infection. The other study looked at the taste profile of different suspensions in healthy adults and also involved RSV-related study material.
Who the studies were designed for
One trial focused on infants and children with RSV infection affecting the lower airways and lungs. This is an important group because young children can be more affected by breathing infections.
The second trial enrolled healthy adult participants. In that study, the main goal was not to treat illness, but to learn how the study medicine tasted in different forms.
What the trials measured
The infant and child study measured treatment-emergent adverse events, which means health problems that start or get worse after the study medicine is given. It also measured adverse events and serious adverse events that led to stopping the study medicine, plus clinically significant abnormal laboratory values, ECG parameters, and vital signs.
The healthy adult study used a palatability questionnaire to score mouth feel, bitterness, sweetness, sourness, saltiness, tongue or mouth burn, and overall liking. Palatability means how acceptable a medicine is to the senses, especially taste and mouth feel.
Trial status and enrollment
The RSV lower respiratory tract infection study was listed as Withdrawn and planned to enroll 108 participants. A withdrawn study means it did not move forward as planned before enough participants were enrolled or before completion.
The taste-profile study was listed as Completed and enrolled 12 healthy adults. This small sample size fits an early study that is mainly meant to gather initial information.
Key points for patients
These trials are not large treatment studies yet; they are early research studies meant to learn basic information about Sisunatovir. The research questions are different in each study: one is about safety in young children with RSV, and the other is about taste in healthy adults.
For the child study, the main focus was on whether the study medicine could be given safely and whether the body showed any concerning changes in tests or heart tracing. For the adult study, the main focus was whether the different suspensions were acceptable to taste and mouth feel.